DBV Technologies(US:DBVT)2026-03-26 21:25Financial Performance - For the year ended December 31, 2025, operating income totaled $5.6 million, an increase from $4.2 million in 2024[12] - Net loss for 2025 was $147.0 million, compared to $113.9 million in 2024, with a net loss per share of $1.05[16] - Cash and cash equivalents as of December 31, 2025, were $194 million, significantly up from $32.5 million in 2024[19] - Total net cash flows from financing activities in 2025 were $276.2 million, compared to $0.6 million in 2024[19] Research and Development - Research and development expenses rose by $27.3 million in 2025, driven by the anticipated BLA submission for children aged 4-7 years in the first half of 2026[13] - The company plans to submit a BLA for 1-3 year olds in the second half of 2026 under an Accelerated Approval Pathway[13] - A supplemental safety study, COMFORT Toddlers, was initiated for peanut-allergic toddlers aged 1 to 3 years[8] Product Development and Commercialization - The company announced a private placement financing of up to $306.9 million to support the VIASKIN® Peanut Patch development and potential U.S. launch[7] - Positive topline results were reported from the Phase 3 VITESSE trial for the VIASKIN® Peanut Patch in children aged 4 to 7 years[5] - The company is preparing for the commercialization of the VIASKIN® Peanut Patch, focusing on children aged 1-7 years[2]